All Atrial fibrillation articles
This promotional webinar was organised and funded by the Bristol Myers Squibb/Pfizer Alliance and is intended for UK healthcare professionals only.
Click HERE to view ELIQUIS (apixaban) prescribing information and adverse events reporting
Adverse events should be reported. Reporting forms and information can be found at: UK – www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store Adverse events should also be reported to Bristol-Myers Squibb via email@example.com or 0800 731 1736 (UK).
432-GB-2200204 May 2022
Transitioning eligible patients with NVAF from warfarin to direct oral anticoagulants—a patient case study
This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto▼(rivaroxaban)
PP-XAR-GB-2415 January 2022
Changes to the NICE atrial fibrillation (AF) guideline and anticoagulation treatment options—what do they mean to you?
This promotional animation has been commissioned by Bayer plc and developed in partnership with Guidelines.
View Xarelto▼ (rivaroxaban) prescribing information and adverse event reporting
PP-XAR-GB-2154 December 2021
Patients with atrial fibrillation report fewer adverse renal outcomes and a slower decline in renal function on rivaroxaban compared with warfarin
Independent professional body guideline
Recommendations for primary care on the role of oral anticoagulant treatment in people with non-valvular atrial fibrillation.
Read the latest recommendations on the management of atrial fibrillation and ventricular arrhythmias in acute coronary syndrome, coronary heart disease, and left-ventricular dysfunction as well as arrhythmias associated with cardiac arrest and coronary artery bypass graft.